List view / Grid view

Janssen Pharmaceuticals Inc.

FDA approves Invega Trinza four-times-a-year treatment for schizophrenia

20 May 2015 | By Victoria White

The FDA have approved Janssen’s New Drug Application (NDA) for the three-month long-acting atypical antipsychotic Invega Trinza...

news

Johnson & Johnson announces groundbreaking partnership to evaluate compassionate use requests of investigational medicines

7 May 2015 | By Victoria White

J&J has announced a first-of-its-kind partnership that enlists a third party to review compassionate use requests made for investigational medicines...

news

EU’s next-gen ‘healthcare heroes’ to forge ahead at European Health Parliament

24 April 2015 | By Victoria White

Young healthcare enthusiasts involved in the European Health Parliament will meet on Friday to push ahead with their ideas on Europe's future healthcare...

news

Janssen announces results for its hepatitis C treatment simeprevir

24 April 2015 | By Victoria White

Janssen Sciences Ireland UC announced results for its hepatitis C treatment simeprevir at The International Liver Congress™ 2015...

news

Ichor and Janssen to collaborate to develop and commercialise immunotherapies for chronic Hepatitis B

13 April 2015 | By Victoria White

Ichor Medical Systems has announced that it has entered into a product development collaboration and worldwide license agreement with Janssen...

news

New study finds three-month paliperidone palmitate significantly delayed time to relapse in patients with schizophrenia

1 April 2015 | By Victoria White

Three-month paliperidone palmitate significantly delayed time to relapse compared to placebo in patients with schizophrenia, according to a Phase 3 study...

news

Phase 2 COSMOS study results published in The Lancet demonstrate efficacy and safety of Janssen’s once-daily imeprevir

29 July 2014 | By Janssen

... in all oral 12-week combination with sofosbuvir for genotype 1 chronic hepatitis C.

news

Janssen announces License Agreement with Vertex to develop novel treatment for influenza A

19 June 2014 | By Johnson & Johnson

Janssen Pharmaceuticals, Inc. announced that it has entered into an exclusive license agreement with Vertex Pharmaceuticals...

news

Supplemental New Drug Applications for once-monthly long-acting therapy INVEGA® SUSTENNA® submitted to the U.S. FDA for the treatment of schizoaffective disorder

14 May 2014 | By Johnson & Johnson

Janssen Pharmaceuticals, Inc., announced the submission of supplemental New Drug Applications for once-monthly atypical long-acting antipsychotic INVEGA® SUSTENNA® (paliperidone palmitate) to the U.S. Food and Drug Administration...

news

Study found INVEGA® SUSTENNA® once-monthly long-acting therapy delayed time to and reduced risk of relapse in individuals with schizoaffective disorder as monotherapy and adjunctive therapy

7 May 2014 | By Johnson & Johnson

Demonstrated significant efficacy in manic and depressive mood symptoms and psychosis, and improved patient functioning...

news

Landmark study shows once-monthly long-acting therapy INVEGA® SUSTENNA® significantly delayed time to relapse in patients with schizophrenia compared to daily oral antipsychotic

6 May 2014 | By Johnson & Johnson

Janssen Pharmaceuticals, Inc., announced the results of its landmark PRIDE trial...

news

Johnson & Johnson and its Subsidiaries conclude previously disclosed settlement agreements with U.S. Department of Justice and 45 States

4 November 2013 | By Johnson & Johnson

The resolution includes total settlement amounts of approximately $2 billion to the federal government...

news

AstraZeneca enters co-promotion agreement with Janssen in Japan for innovative prostate cancer treatment

11 October 2013 | By AstraZeneca

AstraZeneca announced that it has entered into an agreement to co-promote, an innovative oral therapy for the treatment of patients with prostate cancer...

news

Janssen acquires investigational NS5A inhibitor for the treatment of Hepatitis C from GlaxoSmithKline

8 October 2013 | By Janssen Pharmaceuticals, Inc

"We're excited to add GSK2336805 to our existing portfolio of direct-acting antivirals (DAAs)...

news

U.S. FDA approves INVOKANA™ (canagliflozin) for the treatment of adults with Type 2 diabetes

29 March 2013 | By Janssen Pharmaceuticals

The U.S. FDA has approved INVOKANA™...

Cookie	Description
cookielawinfo-checkbox-advertising-targeting	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID	This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged	This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.

Cookie	Description
cf_ob_info	This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob	This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only	This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush	This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db	This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC	This cookie is set by Youtube and is used to track the views of embedded videos.

Cookie	Description
bcookie	This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS	This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang	This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc	This cookie is set by LinkedIn and used for routing.
lissc	This cookie is set by LinkedIn share Buttons and ad tags.
vuid	We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId	This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule	This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session	This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues	This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga	This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat	This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid	This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.

Cookie	Description
advanced_ads_browser_width	This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions	This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info	This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer	This cookie is set by Advanced Ads and sets the referrer URL.
bscookie	This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE	This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr	This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory	This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE	This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.

Recommended

Janssen Pharmaceuticals Inc.